Dashboard
Manage Tickers

LLYELI LILLY & Co

NYSE lilly.com


$ 949.13 $ -1.95 (-0.21 %)    

Monday, 26-Aug-2024 10:32:23 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 474.62 $ -5.31 (-1.11 %)
DIA $ 414.31 $ 1.46 (0.35 %)
SPY $ 561.14 $ -2.05 (-0.36 %)
TLT $ 98.49 $ -0.16 (-0.16 %)
GLD $ 232.69 $ -0.79 (-0.34 %)
$ 952.74
$ 951.08
$ 948.51 x 200
$ 950.00 x 200
$ 943.19 - $ 951.73
$ 513.12 - $ 972.53
2,063,309
na
905.51B
$ 0.59
$ 123.33
TBD
na
na ($ 0.01)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 04-30-2024 03-31-2024 10-Q
3 02-21-2024 12-31-2023 10-K
4 11-02-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 04-27-2023 03-31-2023 10-Q
7 02-22-2023 12-31-2022 10-K
8 11-01-2022 09-30-2022 10-Q
9 08-04-2022 06-30-2022 10-Q
10 04-29-2022 03-31-2022 10-Q
11 02-23-2022 12-31-2021 10-K
12 10-27-2021 09-30-2021 10-Q
13 08-03-2021 06-30-2021 10-Q
14 04-30-2021 03-31-2021 10-Q
15 02-17-2021 12-31-2020 10-K
16 10-28-2020 09-30-2020 10-Q
17 07-31-2020 06-30-2020 10-Q
18 05-01-2020 03-31-2020 10-Q
19 02-19-2020 12-31-2019 10-K
20 10-25-2019 09-30-2019 10-Q
21 08-02-2019 06-30-2019 10-Q
22 05-02-2019 03-31-2019 10-Q
23 02-19-2019 12-31-2018 10-K
24 11-06-2018 09-30-2018 10-Q
25 07-25-2018 06-30-2018 10-Q
26 04-27-2018 03-31-2018 10-Q
27 02-20-2018 12-31-2017 10-K
28 10-27-2017 09-30-2017 10-Q
29 07-28-2017 06-30-2017 10-Q
30 05-01-2017 03-31-2017 10-Q
31 02-21-2017 12-31-2016 10-K
32 10-28-2016 09-30-2016 10-Q
33 07-28-2016 06-30-2016 10-Q
34 04-29-2016 03-31-2016 10-Q
35 02-19-2016 12-31-2015 10-K
36 10-30-2015 09-30-2015 10-Q
37 07-30-2015 06-30-2015 10-Q
38 04-30-2015 03-31-2015 10-Q
39 02-19-2015 12-31-2014 10-K
40 10-29-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

eli-lillys-alzheimers-drug-faces-uk-agency-block-after-biogens-medicine-rejection-over-cost-safety
Eli Lilly's Alzheimer's Drug Faces UK Agen...
08/26/2024 12:45:22

The NHS is expected to block the Alzheimer's drug donanemab due to safety risks and high costs following NICE's recent ...

Core News & Articles
U.S. CDC Says Free At Home, Covid 19 Test ...
08/23/2024 15:35:46

- Press Conference

exploring-the-competitive-space-eli-lilly-versus-industry-peers-in-pharmaceuticals
Exploring The Competitive Space: Eli Lilly...
08/23/2024 15:00:26

check-out-what-whales-are-doing-with-lly
Check Out What Whales Are Doing With LLY
08/22/2024 14:02:12

oblique-therapeutics-enters-into-research-collaboration-agreement-with-eli-lilly-to-apply-abiprot-to-generate-antibodies-to-high-value-targets
Oblique Therapeutics Enters Into Research ...
08/22/2024 11:42:03

https://www.prnewswire.com/news-releases/oblique-therapeutics-has-entered-a-research-collaboration-agreement-with-eli-lilly-and...

wegovy-now-available-through-sesames-249-monthly-compounded-program-despite-supply-shortages
Wegovy Now Available Through Sesame's $249...
08/21/2024 15:44:23

Sesame introduces an affordable weight loss program with compounded versions of Wegovy amid supply shortages. The program provi...

novo-nordisk-vs-eli-lilly-beyond-the-weight-loss-drug-battle
Novo Nordisk Vs. Eli Lilly: Beyond The Wei...
08/21/2024 12:51:04

Novo Nordisk and Eli Lilly are competing for the obesity-drug market, but their growth plans extend beyond weight-loss treatmen...

asia-mixed-european-markets-advance-gold-stays-near-all-time-high-while-dollar-gains---global-markets-today-while-us-slept
Asia Mixed, European Markets Advance; Gold...
08/21/2024 11:37:03

US stock markets close lower, breaking 8-day winning streak as investors pause before economic symposium. Energy stocks decline...

wall-street-eases-bonds-rise-us-dollar-falls-to-8-month-low-whats-driving-markets-tuesday
Wall Street Eases, Bonds Rise, US Dollar F...
08/20/2024 17:45:35

It’s a relatively uneventful session on Wall Street, but with a slightly worsening risk sentiment as all U.S. equity indices tr...

fabrinet-posts-strong-earnings-joins-amer-sports-hawaiian-holdings-and-other-big-stocks-moving-higher-on-tuesday
Fabrinet Posts Strong Earnings, Joins Amer...
08/20/2024 14:07:32

watching-eli-lilly--co-live-on-cnbc-ceo-david-ricks-discusses-weight-loss-drugs
Watching Eli Lilly & Co.; Live On CNBC, CE...
08/20/2024 13:46:17

-CNBC

eli-lillys-famed-obesitydiabetes-treatment-tirzepatide-shows-potential-to-cut-risk-of-developing-diabetes-sustained-weight-loss-over-3-years
Eli Lilly's Famed Obesity/Diabetes Treatme...
08/20/2024 12:17:00

Eli Lilly's SURMOUNT-1 three-year study reveals tirzepatide's effectiveness in reducing type 2 diabetes risk and achiev...

Core News & Articles
Organon Has Expanded Its Agreement With El...
08/20/2024 11:34:35

lilly-announces-results-from-surmount-1-three-year-study-of-tirzepatide-showing-weekly-tirzepatide-injections-reduced-risk-of-progression-to-type-2-diabetes-by-94-in-adults-with-pre-diabetes-and-obesity
Lilly Announces Results From SURMOUNT-1 Th...
08/20/2024 10:52:27

10-health-care-stocks-whale-activity-in-todays-session
10 Health Care Stocks Whale Activity In To...
08/19/2024 17:35:23

cantor-fitzgerald-reiterates-overweight-on-eli-lilly-maintains-885-price-target
Cantor Fitzgerald Reiterates Overweight on...
08/19/2024 16:22:08

Cantor Fitzgerald analyst Louise Chen reiterates Eli Lilly (NYSE:LLY) with a Overweight and maintains $885 price target.

telehealth-firm-hims--hers-health-rides-high-on-demand-for-copycat-weight-loss-drugs-amid-supply-shortages
Telehealth Firm Hims & Hers Health Rides H...
08/19/2024 13:24:02

Hims & Hers Health has seen its stock rise over 120% due to soaring demand for its affordable compounded GLP-1 weight-loss ...

doctors-struggle-to-secure-medicare-coverage-for-heart-patients-on-novo-nordisks-wegovy
Doctors Struggle to Secure Medicare Covera...
08/16/2024 17:59:37

Medicare patients struggle to access Novo Nordisk's Wegovy for heart disease treatment despite new guidelines, with many pl...

roche-misses-out-on-weight-loss-blockbuster-drug-now-playing-catch-up-in-booming-market
Roche Misses Out On Weight-Loss Blockbuste...
08/16/2024 17:56:16

Roche missed out on acquiring a potential blockbuster weight-loss drug, now owned by Eli Lilly, in 2018. The drug, orforglipron...

guggenheim-maintains-buy-on-eli-lilly-raises-price-target-to-1030
Guggenheim Maintains Buy on Eli Lilly, Rai...
08/16/2024 17:09:09

Guggenheim analyst Seamus Fernandez maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $884 to $1030.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION